{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:44:47Z","timestamp":1783035887695,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001215","name":"La Trobe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001215","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cachexia is a complex syndrome characterized by unintentional weight loss, progressive muscle wasting and loss of appetite. Anti-Fn14 antibody (mAb 002) targets the TWEAK receptor (Fn14) in murine models of cancer cachexia and can extend the lifespan of mice by restoring the body weight of mice. Here, we investigated glucose metabolic changes in murine models of cachexia via [<jats:sup>18<\/jats:sup>F]FDG PET imaging, to explore whether Fn14 plays a role in the metabolic changes that occur during cancer cachexia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]FDG PET\/MRI imaging was performed in cachexia-inducing tumour models versus models that do not induce cachexia. SUV<jats:sub>average<\/jats:sub> was calculated for all tumours via volume of interest (VOI) analysis of PET\/MRI overlay images using PMOD software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]FDG PET imaging demonstrated increased tumour and brain uptake in cachectic versus non-cachectic tumour-bearing mice. Therapy with mAb 002 was able to reduce [<jats:sup>18<\/jats:sup>F]FDG uptake in tumours (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05, <jats:italic>n<\/jats:italic>\u2009=\u20093). Fn14 KO tumours did not induce body weight loss and did not show an increase in [<jats:sup>18<\/jats:sup>F]FDG tumour and brain uptake over time. In non-cachectic mice bearing Fn14 KO tumours, [<jats:sup>18<\/jats:sup>F]FDG tumour uptake was significantly lower (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) than in cachectic mice bearing Fn14 WT counterparts. As a by-product of glucose metabolism, l-lactate production was also increased in cachexia-inducing tumours expressing Fn14.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results demonstrate that Fn14 receptor activation is linked to glucose metabolism of cachexia-inducing tumours.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00259-024-06836-1","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:05:15Z","timestamp":1722027915000},"page":"3854-3862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting Fn14 as a therapeutic target for cachexia reprograms the glycolytic pathway in tumour and brain in mice"],"prefix":"10.1007","volume":"51","author":[{"given":"Ingrid Julienne Georgette","family":"Burvenich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Danielle","family":"Osellame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rigopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhi","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Johannes","family":"Hoogenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-295X","authenticated-orcid":false,"given":"Andrew Mark","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"6836_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jpainsymman.2006.05.012","volume":"32","author":"JB Hopkinson","year":"2006","unstructured":"Hopkinson JB, Wright DN, McDonald JW, Corner JL. The prevalence of concern about weight loss and change in eating habits in people with advanced cancer. J Pain Symptom Manage. 2006;32:322\u201331.","journal-title":"J Pain Symptom Manage"},{"key":"6836_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1191\/0269216302pm593oa","volume":"16","author":"K Poole","year":"2002","unstructured":"Poole K, Froggatt K. Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional? Palliat Med. 2002;16:499\u2013506.","journal-title":"Palliat Med"},{"key":"6836_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","volume":"4","author":"SF Schmidt","year":"2018","unstructured":"Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer Cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4:849\u201360.","journal-title":"Trends Cancer"},{"key":"6836_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793\u20139.","journal-title":"Clin Nutr"},{"key":"6836_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1200\/JCO.1996.14.1.135","volume":"14","author":"KM Rowland Jr","year":"1996","unstructured":"Rowland KM Jr., Loprinzi CL, Shaw EG, Maksymiuk AW, Kuross SA, Jung SH, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate\/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 1996;14:135\u201341.","journal-title":"J Clin Oncol"},{"key":"6836_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/528182a","volume":"528","author":"C Lok","year":"2015","unstructured":"Lok C. Cachexia: the last illness. Nature. 2015;528:182\u20133.","journal-title":"Nature"},{"key":"6836_CR7","doi-asserted-by":"crossref","unstructured":"Cao Z, Zhao K, Jose I, Hoogenraad NJ, Osellame LD. Biomarkers for Cancer Cachexia: a Mini Review. Int J Mol Sci. 2021; 22.","DOI":"10.3390\/ijms22094501"},{"key":"6836_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1600-065X.2011.01054.x","volume":"244","author":"LC Burkly","year":"2011","unstructured":"Burkly LC, Michaelson JS, Zheng TS. TWEAK\/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev. 2011;244:99\u2013114.","journal-title":"Immunol Rev"},{"key":"6836_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrd2488","volume":"7","author":"JA Winkles","year":"2008","unstructured":"Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411\u201325.","journal-title":"Nat Rev Drug Discov"},{"key":"6836_CR10","doi-asserted-by":"publisher","first-page":"8455","DOI":"10.1074\/jbc.274.13.8455","volume":"274","author":"CN Lynch","year":"1999","unstructured":"Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem. 1999;274:8455\u20139.","journal-title":"J Biol Chem"},{"key":"6836_CR11","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1172\/JCI23486","volume":"115","author":"A Jakubowski","year":"2005","unstructured":"Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest. 2005;115:2330\u201340.","journal-title":"J Clin Invest"},{"key":"6836_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1083\/jcb.200801010","volume":"182","author":"JE Vince","year":"2008","unstructured":"Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol. 2008;182:171\u201384.","journal-title":"J Cell Biol"},{"key":"6836_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.tcb.2012.08.001","volume":"22","author":"L Tornatore","year":"2012","unstructured":"Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling pathway: integrating metabolism with inflammation. Trends Cell Biol. 2012;22:557\u201366.","journal-title":"Trends Cell Biol"},{"key":"6836_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-4598-12-86","volume":"12","author":"B Hoesel","year":"2013","unstructured":"Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer. 2013;12:86.","journal-title":"Mol Cancer"},{"key":"6836_CR15","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.cell.2015.08.031","volume":"162","author":"AJ Johnston","year":"2015","unstructured":"Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, et al. Targeting of Fn14 prevents Cancer-Induced Cachexia and Prolongs Survival. Cell. 2015;162:1365\u201378.","journal-title":"Cell"},{"key":"6836_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.beem.2012.05.003","volume":"26","author":"LD Osellame","year":"2012","unstructured":"Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012;26:711\u201323.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"6836_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/421583a","volume":"421","author":"P Rich","year":"2003","unstructured":"Rich P. Chemiosmotic coupling: the cost of living. Nature. 2003;421:583.","journal-title":"Nature"},{"key":"6836_CR18","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1007\/s00259-022-05918-2","volume":"49","author":"Z Kiamanesh","year":"2022","unstructured":"Kiamanesh Z, Ayati N, Sadeghi R, Hawkes E, Lee ST, Scott AM. The value of FDG PET\/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review. Eur J Nucl Med Mol Imaging. 2022;49:4661\u201376.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6836_CR19","doi-asserted-by":"crossref","unstructured":"Murphy PS, Galette P, van der Aart J, Janiczek RL, Patel N, Brown A. The role of clinical imaging in oncology drug development: progress and new challenges. Br J Radiol. 2023: 20211126.","DOI":"10.1259\/bjr.20211126"},{"key":"6836_CR20","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1158\/0008-5472.CAN-11-1095","volume":"71","author":"MF Penet","year":"2011","unstructured":"Penet MF, Gadiya MM, Krishnamachary B, Nimmagadda S, Pomper MG, Artemov D, et al. Metabolic signatures imaged in cancer-induced cachexia. Cancer Res. 2011;71:6948\u201356.","journal-title":"Cancer Res"},{"key":"6836_CR21","doi-asserted-by":"publisher","first-page":"900712","DOI":"10.3389\/fonc.2022.900712","volume":"12","author":"S Olaechea","year":"2022","unstructured":"Olaechea S, Gannavarapu BS, Alvarez C, Gilmore A, Sarver B, Xie D, et al. Primary tumor Fluorine-18 fluorodeoxydglucose ((18)F-FDG) is Associated with Cancer-Associated Weight loss in Non-small Cell Lung Cancer (NSCLC) and portends worse survival. Front Oncol. 2022;12:900712.","journal-title":"Front Oncol"},{"key":"6836_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","volume":"134","author":"PP Hsu","year":"2008","unstructured":"Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703\u20137.","journal-title":"Cell"},{"key":"6836_CR23","doi-asserted-by":"publisher","first-page":"8927","DOI":"10.1158\/0008-5472.CAN-06-1501","volume":"66","author":"JW Kim","year":"2006","unstructured":"Kim JW, Dang CV. Cancer\u2019s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927\u201330.","journal-title":"Cancer Res"},{"key":"6836_CR24","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the Tumor Microenvironment is a driver of Cancer Progression. Cell. 2015;162:1229\u201341.","journal-title":"Cell"},{"key":"6836_CR25","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"PC Ho","year":"2015","unstructured":"Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162:1217\u201328.","journal-title":"Cell"},{"key":"6836_CR26","first-page":"555","volume":"166","author":"S Vyas","year":"2016","unstructured":"Vyas S, Zaganjor E, Haigis MC. Mitochondria Cancer Cell. 2016;166:555\u201366.","journal-title":"Mitochondria Cancer Cell"},{"key":"6836_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molcel.2016.02.011","volume":"61","author":"WX Zong","year":"2016","unstructured":"Zong WX, Rabinowitz JD, White E. Mitochondria and Cancer. Mol Cell. 2016;61:667\u201376.","journal-title":"Mol Cell"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06836-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06836-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06836-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:20:57Z","timestamp":1730366457000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06836-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["6836"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06836-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were approved by the Austin Health Animal Ethics Committee (17\/11\/2016, A2016\/05344) and were conducted in compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes 8th edition 2013.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Ingrid Julienne Georgette Burvenich is an Editorial Board Member of the EJNMMI and Andrew Mark Scott is an Editor of the EJNMMI.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}